European Pharmaceutical Review

JUNE 27, 2024

Immunotherapy in oncology “The addition of pembrolizumab to chemotherapy represents a new frontline therapeutic option for patients with primary advanced or recurrent endometrial carcinoma” Moreover, last week saw US regulatory approval of a combination treatment for endometrial cancer : KEYTRUDA (pembrolizumab) plus chemotherapy.

Chemotherapy 64

Chemotherapy FDA 64

pharmaphorum

AUGUST 9, 2022

The data provide proof-of-principle for the use of MET-targeting drugs to offset Tagrisso resistance, and charts a way forward towards regulatory approvals of the combination as an alternative to chemotherapy for these patients. It is AZ’s biggest-selling drug, with sales topping $5 billion last year.

Chemotherapy 52

Chemotherapy Labelling FDA 52

pharmaphorum

OCTOBER 19, 2022

Zanidatamab is an HER2-targeted bispecific antibody with multiple novel mechanisms of action that has demonstrated ‘compelling’ anti-tumour activity in several HER2-expressing cancers, operating both as a monotherapy and in combination with chemotherapy and other agents. Zanidatamab is based on Zymeworks’ Azymetric platform.

Chemotherapy 40

Chemotherapy FDA 40

Roots Analysis

OCTOBER 4, 2023

One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy. during the period 2023-2035.

Chemotherapy 40

Chemotherapy Immunization FDA 40

pharmaphorum

MARCH 9, 2021

Now, people living with particular types of lymphoma have individualised options beyond chemotherapy for the first time.”. Our strategy for 2020-2025: Changing how people live with lymphoma. Last accessed March 2021. Lymphoma Action. Fundraising Support Assistance: Recruitment Pack. 2018, page 3. Lymphoma Action. Available at: [link].

Chemotherapy 52

Chemotherapy Communication Immunization 52

pharmaphorum

AUGUST 22, 2021

The PD-1 inhibitor has been approved to treat patients regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status, and UC becomes the third indication for Opdivo as an adjuvant therapy after oesophageal/gastro-oesophageal cancer and melanoma.

FDA 78

FDA Chemotherapy Immunization 78

The Checkup by Singlecare

MARCH 20, 2025

28, 2025, the FDA announced the approval of Ozempic for reducing the risk of worsening kidney disease and cardiovascular death in adults with chronic kidney disease and Type 2 diabetes. In addition, these agents also decreased the incidence of major cardiovascular events, including heart attacks and strokes, by 13%.

FDA 52

FDA Chemotherapy Patient Care 52

PQA

NOVEMBER 1, 2024

Monitoring Oral Chemotherapy Outcomes A new study by specialty pharmacists from Vanderbilt Specialty Pharmacy detailed that a tailored clinical monitoring schedule focused on oral oncolytics with high rates of adverse events (AEs) slashed treatment interruptions by more than 50% and significantly reduced medication-related hospitalizations.

Specialty Pharmacies 52

Specialty Pharmacies Vaccines Chemotherapy Immunization 52

Hospital Pharmacy Europe

MARCH 17, 2025

The MHRA green light follows the approval of lazertinib by the European Commission in January 2025 for the same treatment combination and indication. Clinical trial results have shown the amivantamab-lazertinib combination to have superior progression-free survival and overall survival compared to the current standard of care osimertinib.

Chemotherapy 52

Chemotherapy Labelling Hospitals 52

European Pharmaceutical Review

FEBRUARY 3, 2025

EMAs human medicines committee (CHMP) recommended eight medicines for EU marketing authorisation at its January 2025 meeting. Biosimilars given a positive opinion Dyrupeg (pegfilgrastim) to reduce the duration of neutropenia and help prevent febrile neutropenia following chemotherapy.

Generic Medicine 52

Generic Medicine Vaccines Chemotherapy Immunization 52